ClinicalTrials.gg
TerminatedNCT06011577RELIGHTUpdated Jul 10, 2026Results posted

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

A Phase 3 interventional study of REL-1017 and Placebo in Major Depressive Disorder and Depression, sponsored by Levomecor Inc.. Terminated at 36 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Levomecor Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Study REL-1017-304 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation conducted in study REL-1017-302. Safety assessments were performed in both studies in accordance with the study protocols

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
996th of 1,323
27 · median 70
Started
2023
with 72 others
Phase 3
240 of 1,500
21 open now
Registered
1,273rd of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 996th largest by enrollment of the 1,323 interventional ones that give a count, is one of 73 that started in 2023, is one of 240 in phase 3, and was the 1,273rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).

Read the detailed description

This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder in patients with inadequate response to ongoing background antidepressant treatment. Eligible patients will continue to take their background antidepressant therapy and be randomized in a 1:1 ratio to treatment with REL-1017 or placebo for a 4 week treatment period.

03

Conditions studied

  • Major Depressive Disorder
  • Depression

Keywords

  • REL-1017
  • esmethadone
  • Relmada
  • antidepressant
  • adjunctive
  • NMDA receptor antagonist
  • Relight
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.0 and 35.0 kg/m2.
  • Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview for (SCID-5) for MDD.
  • Inadequate response to 1 to 3 adequate antidepressant treatments in the current MDE.

Exclusion criteria

Exclusion Criteria:

  • Psychiatric hospitalization during the current major depressive episode.
  • History or presence of health conditions which in the opinion of the Investigator would negatively impact the safety of the participant.
  • Participants who, in the Investigator's judgment, are at significant risk for suicide.
  • Pregnant or planning to become pregnant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    REL-1017 25 mg

    During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)

    Drug: REL-1017

  • Placebo comparator
    Placebo

    During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT)

    Drug: Placebo

Interventions

  • REL-1017 tablet

    Also known as: esmethadone

  • DrugPlacebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score.

    Time frame: Baseline and Day 28

Secondary outcomes

  1. Change From Baseline to Day 7 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 7.Change was calculated as Day 7 score minus Baseline score.

    Time frame: Baseline and Day 7

07

Results

Posted Jul 10, 2026
Limitations and caveats
Study REL-1017-304 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation conducted in study REL-1017-302. Safety assessments were performed in both studies in accordance with the study protocols.

Participant flow

Participant flow — Overall Study
MilestoneREL-1017Placebo
Started1413
Completed1313
Not completed10
Withdrew: Study terminated by sponsor10

Outcome measures

PrimaryChange From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score.

Time frame:
Baseline and Day 28
Reported as:
Mean · Scores on a scale (MADRS10)
Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
Scores on a scale (MADRS10)REL-1017Placebo
Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-16.8 ± 7.62-13.4 ± 9.55
SecondaryChange From Baseline to Day 7 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 7.Change was calculated as Day 7 score minus Baseline score.

Time frame:
Baseline and Day 7
Reported as:
Mean · MADRS10 score
Change From Baseline to Day 7 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
MADRS10 scoreREL-1017Placebo
Change From Baseline to Day 7 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-8.9 ± 6.84-5.1 ± 5.66

Adverse events

Collected over TEAE that starts or worsens at any time after initiation of study drug collected up to 14 days post treatment (Day 42).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REL-10170/14 (0%)0/14 (0%)9/14 (64.3%)
Placebo0/13 (0%)0/13 (0%)3/13 (23.1%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventREL-1017Placebo
Urinary tract infectionInfections and infestations2/141/13
Nasopharyngitis/ Common coldInfections and infestations1/141/13
COVID-19Infections and infestations0/141/13
Decrease Appetite/Poor AppetiteMetabolism and nutrition disorders1/140/13
Dry MouthGastrointestinal disorders1/140/13
Fatigue/TirenessGeneral disorders1/140/13
Dysgeusia/Aluminum taste in the mouthNervous system disorders1/140/13
Pruritus/Itching all over the bodySkin and subcutaneous tissue disorders1/140/13
Disness/ Light headachenessNervous system disorders1/140/13
Abdominal distention/ BloatingGastrointestinal disorders1/140/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)REL-1017PlaceboTotal
<=18 years000
Between 18 and 65 years141327
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)REL-1017PlaceboTotal
Female121022
Male235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REL-1017PlaceboTotal
American Indian or Alaska Native011
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White141125
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REL-1017PlaceboTotal
Hispanic or Latino8614
Not Hispanic or Latino6713
Unknown or Not Reported000
MADRS10 at baseline
MADRS10 at baseline(Scores on a scale (MADRS10))REL-1017PlaceboTotal
Mean34.2 ± 4.4132.3 ± 3.7333.3 ± 4.13
08

Study locations

36 sites
  • Relmada Site
    Dothan, Alabama 36303, United States
  • Relmada Site
    Homewood, Alabama 35209, United States
  • Relmada Site
    Anaheim, California 92805, United States
  • Relmada Site
    Lafayette, California 94549, United States
  • Relmada Site
    Newport Beach, California 92660, United States
  • Relmada Site
    Orange, California 92868, United States
  • Relmada Site
    Redlands, California 92374, United States
  • Relmada Site
    Sherman Oaks, California 91403, United States
  • Relmada Site
    Farmington, Connecticut 06030, United States
  • Relmada Site
    Brandon, Florida 33511, United States
  • Relmada Site
    Hialeah, Florida 33027, United States
  • Relmada Site
    Jacksonville, Florida 32256, United States
  • Relmada Site
    Miami, Florida 33133, United States
  • Relmada Site
    Miami, Florida 33174, United States
  • Relmada Site
    Okeechobee, Florida 34972, United States
  • Relmada Site
    Tampa, Florida 33607, United States
  • Relmada Site
    Springfield, Illinois 62794, United States
  • Relmada Site
    Baltimore, Maryland 21208, United States
  • Relmada Site
    Mankato, Minnesota 56001, United States
  • Relmada Site
    Toms River, New Jersey 08755, United States
  • Relmada Site
    Brooklyn, New York 11235, United States
  • Relmada Site
    Cedarhurst, New York 11516, United States
  • Relmada Site
    New York, New York 10036, United States
  • Relmada Site
    Philadelphia, Pennsylvania 19104, United States
  • Relmada Site
    Franklin, Tennessee 37067, United States
  • Relmada Site
    Memphis, Tennessee 38119, United States
  • Relmada Site
    Austin, Texas 78712, United States
  • Relmada Site
    Bellaire, Texas 77401, United States
  • Relmada Site
    Friendswood, Texas 77546, United States
  • Relmada Site
    Houston, Texas 77030, United States
  • Relmada Site
    Wichita Falls, Texas 76309, United States
  • Relmada Site
    Clinton, Utah 84015, United States
  • Relmada Site
    Draper, Utah 84020, United States
  • Relmada Site
    Rutland, Vermont 05701, United States
  • Relmada Site
    Charlottesville, Virginia 22903, United States
  • Relmada Site
    Seattle, Washington 98104, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Dec 2024, 16 months.

Results were first posted in Jul 2026, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Aug 25, 2023
StartActual
Aug 17, 2023
Primary completionActual
Dec 19, 2024
CompletionActual
Dec 19, 2024
Results first posted
Jul 10, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06011577
Lead sponsor
Levomecor Inc.
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Aug 17, 2023
Primary completion
Dec 19, 2024
Completion
Dec 19, 2024
Results posted
Jul 10, 2026
Last update
Jul 10, 2026

Study contacts

Paul Greene, PhD
study director · Relmada Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-methadone

Start the discussion